The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 354:2443-2451 June 8, 2006 Number 23
NextNext

Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors
William O. Cooper, M.D., M.P.H., Sonia Hernandez-Diaz, M.D., Dr.P.H., Patrick G. Arbogast, Ph.D., Judith A. Dudley, B.S., Shannon Dyer, B.S., Patricia S. Gideon, R.N., Kathi Hall, B.S., and Wayne A. Ray, Ph.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
 by Friedman, J.M.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background Use of angiotensin-converting–enzyme (ACE) inhibitors during the second and third trimesters of pregnancy is contraindicated because of their association with an increased risk of fetopathy. In contrast, first-trimester use of ACE inhibitors has not been linked to adverse fetal outcomes. We conducted a study to assess the association between exposure to ACE inhibitors during the first trimester of pregnancy only and the risk of congenital malformations.

Methods We studied a cohort of 29,507 infants enrolled in Tennessee Medicaid and born between 1985 and 2000 for whom there was no evidence of maternal diabetes. We identified 209 infants with exposure to ACE inhibitors in the first trimester alone, 202 infants with exposure to other antihypertensive medications in the first trimester alone, and 29,096 infants with no exposure to antihypertensive drugs at any time during gestation. Major congenital malformations were identified from linked vital records and hospitalization claims during the first year of life and confirmed by review of medical records.

Results Infants with only first-trimester exposure to ACE inhibitors had an increased risk of major congenital malformations (risk ratio, 2.71; 95 percent confidence interval, 1.72 to 4.27) as compared with infants who had no exposure to antihypertensive medications. In contrast, fetal exposure to other antihypertensive medications during only the first trimester did not confer an increased risk (risk ratio, 0.66; 95 percent confidence interval, 0.25 to 1.75). Infants exposed to ACE inhibitors were at increased risk for malformations of the cardiovascular system (risk ratio, 3.72; 95 percent confidence interval, 1.89 to 7.30) and the central nervous system (risk ratio, 4.39; 95 percent confidence interval, 1.37 to 14.02).

Conclusions Exposure to ACE inhibitors during the first trimester cannot be considered safe and should be avoided.


Source Information

From the Departments of Pediatrics (W.O.C., S.D.), Biostatistics (P.G.A.), and Preventive Medicine (J.A.D., P.S.G., K.H., W.A.R.), Vanderbilt University School of Medicine, Nashville; and the Slone Epidemiology Center, Boston University, Boston (S.H.-D.).

Address reprint requests to Dr. Cooper at the Department of Pediatrics, Vanderbilt University School of Medicine, AA-0216 MCN, Nashville, TN 37232, or at william.cooper{at}vanderbilt.edu.

Full Text of this Article


Related Letters:

ACE Inhibitors and Major Congenital Malformations
Scialli A. R., Lione A., Sealey J. E., Itskovitz-Eldor J., Cooper W. O., Ray W. A.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:1280-1281, Sep 21, 2006. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.